Research Protocol
All the reported studies are unicentric based on experiences of individual practitioners and do not give specific factors, which are responsible for a successful prescription for the treatment of warts.
The Central Council for Research in Homoeopathy (CCRH) aims to undertake research that can be translated into a successful clinical practice. With this background, the present study has been designed as a multicentric randomised, double-blind, placebo-controlled trial to evaluate response to homoeopathic treatment for disappearance or resolution of warts and to validate the symptoms of the pre-identified nine drugs on clinical outcome in warts.
The study protocol is in accordance with the Helsinki declaration on human experimentation. [7] Requisite clearance of the Ethical Committee and Scientific Advisory Committee of CCRH had been obtained before undertaking the study. The ethical approval of the study had been obtained from the Ethical Committee of the Council vide letter no: 1-3/2017-18/ CCRH/TECH/CR/WARTS/1372, dated 24.8.17. The trial is registered with the Clinical Trials Registry of India (CTRI), namely CTRI/2018/12/016672 (registered on: 14/12/2018).
Objectives

Primary objective
To evaluate response to homoeopathic treatment for disappearance or resolution of warts.
Secondary objective
To validate the symptoms of the following pre-identified nine drugs on the successful clinical outcome on warts:
1. Antimonium crudum 2. Calcarea carbonicum 3. Causticum 4. Dulcamara 5. Natrum muriaticum 6. Nitric acidicum 7. Ruta graveolens 8. Sulphur 9. Thuja occidentalis.
MaTeRials and MeThods
Settings
The study shall be conducted at different centres of the CCRH located at Agartala, Gudivada, Jaipur, Kolkata, Kottayam, Mumbai, Noida and Puri. The study will be conducted in special dermatology clinics in these research centres. The dermatology clinics are managed by trained homoeopathic practitioners with research experience. The clinics provide routine outpatient department (OPD) care to patients suffering from dermatological disorders using homoeopathic medicines only.
Eligibility criteria
Patients are eligible if they are in the age group of 18-65 years, of either gender, presenting with cutaneous warts. Patients with anogenital or plantar warts would however, be excluded from the study. Patients with bowenoid papulosis, focal epithelial hyperplasia or seborrhoeic keratosis, past history of skin cancer, having undergone treatment with immune-modulating oral medications such as corticosteroids in the past 4 weeks, patients already on homoeopathic treatment for any disease condition, self-reporting cases of HIV, pregnant and lactating women or those with advance disease of vital organs would be excluded from the study.
In all the patients who give consent for participation and fulfil the inclusion criteria, a detailed case taking would be done. Indicated homoeopathic medicine as per symptom similarity would be identified on the basis of the totality of symptoms. Only cases corresponding to the above mentioned pre-identified homoeopathic medicines will be enrolled in the study and randomised. The cases not falling in the above mentioned drug list will not be enrolled in the study. They would be provided standard treatment in the dermatology OPD, and their data will be maintained separately from the study data.
Randomisation and group allocation
Cases enrolled in the study would be randomised into two groups as follows: Groups A and B for each drug with a 1:1 allocation based on computer-based SPSS software. The enrolment number of the patients will be used for the purpose for randomisation and will be maintained for all follow-up visits. Allocation will be concealed till the primary end point is analysed. The allocation codes will be kept with the Principal investigator (PI) and co-investigator (Co-I) at the CCRH headquarters. The randomisation chart allocating patients to the two groups will be sent to the study site along with the study medicines. One group will be administered active drug and the other will be placebo.
Blinding
The study will be a double-blind study, where the investigators at the study sites and the patients will be kept blind about the group allocation. Un-blinding or breaking of the randomisation codes will be done by the study PI at the headquarters after the study has been completed and the database is frozen. The statistician analysing the data will also be kept blind of the allocation of the groups while analysing the data.
Intervention and follow-up
The drugs identified for the trial shall be procured from a Good Manufacturing Practices (GMP)-compliant pharmaceutical firm. 83.1%v/v ethyl alcohol (used as a vehicle to prepare homoeopathic medicines) will be used as placebo. The placebo will be dispensed in sugar globules of standard size 30 identical to the verum in appearance and taste.
The selected medicine would be initially prescribed in 6C potency at the start of the treatment. Dosage schedule will be as per the requirement of the case. During the period of the study, the potency would be raised sequentially as per the need of the case, in pursuance with the homoeopathic principles. Cases would be followed up at fortnightly interval till complete disappearance of all warts or for 6 months, whichever is earlier.
At each follow-up, an assessment would be made of change in the number and size of warts, and any change in associated symptoms. Digital photograph of the site of warts would be made taking into consideration that identity and privacy of the patient is not compromised at any stage.
The participant timeline for each patient is given in Table 1 .
The treatment will be discontinued and patients will be withdrawn early due to non-compliance to treatment or in case of appearance of any adverse drug event.
Sample size
In the study there are 09 pre-identified drugs and 60 cases will be enrolled at each centre which will be randomized into two groups (30 in drug and 30 in placebo group). As there are 08 study centers, the total sample size for the study will be 480 cases.
Outcome assessment
Outcome would be the percentage of warts completely disappeared i.e. the number of warts disappeared.
Data recording and analysis
Data of all cases will be maintained by the PI and the Co-I and will be added in a pre-designed master chart. The case record and follow-up formats have been designed with an intent to capture all symptoms associated with warts relating to the pre-specified drugs, with due consideration to the principles of homoeopathic case taking. There are no leading questions pointing to a specific medicine or group of medicines, yet a broad framework with general questions has been added to ensure that the case is completed in all possible aspects, i.e. both general and particular symptoms.
The copy of complete records of the cases will be sent to the PI at the CCRH headquarters after completion of 6-month follow-up of the case in the study. The master chart would be sent to the CCRH headquarters at the end of the study period.
The study outcome will be analysed according to parametric test for continuous data and non-parametric test for ordinal data. Baseline comparison would be considered for evaluating the randomisation effect. All the statistical results would be reported in 95% confidence interval with confidence level alpha (α) = 0.05. Stratified analysis of the variables potentially associated with healing of warts, namely number, type of warts, pain and age of warts, will be done.
Validation of symptoms would be as per the methods described under prognostic factor research [8] for cases treated successfully by homoeopathic medicines.
discussion
Warts are frequently considered a one-sided disease with lack of symptoms, and therefore constitutional makeup and other individual characteristics are required for prescription. There has been a long-term experience of homoeopaths that warts disappear when well-indicated medicines covering general and particular symptoms are taken care of during prescription. Therefore, this protocol is designed to prescribe in a similar manner using pre-defined homoeopathic medicines while taking into consideration the basic principles of Homoeopathy; only patients requiring any of the study medicines are included and randomised into treatment and control groups.
The protocol has been developed as per the SPIRIT guidelines [9] and shall generate data that can be reported as per the CONSORT guidelines [10] and RedHot supplement for reporting randomised trials of Homoeopathy. [11] For this study, the drugs were identified on the basis of a literature review and most frequently used in the studies reported. The symptoms related to warts, in particular, and skin complaints, in general, have been identified for validation which would be conducted after the analysis of cases on quantifiable parameters to ascertain the efficacy of treatment.
It has been identified that the best way to assess a causal relationship between cure and medicine is the randomised controlled trial (RCT), but this method is not suited for individual cases. Homoeopathy has a unique opportunity to develop its own scientific identity in achieving evidence-based personalised medicine, whereas RCT evidence fails to serve the needs of the individual patient. We can use accepted scientific methods derived from diagnostic research. [12] An interesting aspect of Homoeopathy is that the prescription is 'personalised:' it fits the patient as a whole, not only the is also an answer to the main problem of RCT evidence: it is not personalised. This recent demand for personalised research besides RCT is an excellent opportunity to favour other methods of evidence-based medicine to improve the knowledge in homoeopathic Materia Medica and Repertories. We can compare the homoeopathic prognostic process with the conventional diagnostic process and use research methods that are common in diagnostic research. [13] This study intends to combine both the approaches, where the symptomatology in individual cases would be assessed and compared with those in the control group, to not only identify and quantify the efficacy, but also to identify the symptomatology on the basis of which successful prescriptions have been made.
RCTs on warts will ensure that the evident results in terms of disappearance of warts are attributable neither to the self-limiting nature of the condition nor to placebo effect. Subsequently, the prescribing symptomatology would be validated.
However, such a strategy will be able to derive statistics if sufficient number of cases under each drug vis-a-vis control group are generated. This will further help the profession to draw meaningful symptomatic data to make clinical practice easier by using successful research outcome. Discussion: L'objectif de l'étude est de combiner l'essai randomisé contrôlé avec la validation des symptômes des médicaments préalablement identifiés dans le traitement des verrues. Les symptômes du groupe verum dans chaque cas traité avec succès ont été comparés à ceux du groupe témoin. L'étude pourrait aider à évaluer l'efficacité du traitement et à identifier la symptomatologie sur la base de laquelle des médicaments réussis ont été prescrits.
Contributors
Protocolo de un estudio aleatorizado, controlado con placebo a doble ciego para evaluar la eficacia de los medicamentos homeopáticos predefinidos para el tratamiento de verrugas RESUMEN Fundamentos y objetivos: En la bibliografía, se enumera un gran número de medicamentos homeopáticos para el tratamiento de verrugas. Los estudios sobre verrugas se basan en las experiencias de médicos individuales y no ofrecen factores específicos que permitan establecer una prescripción satisfactoria para el tratamiento de las verrugas. El presente estudio se diseñó como un ensayo aleatorizado, controlado con placebo, a doble ciego para evaluar la respuesta al tratamiento para la desaparición o resolución de las verrugas y validar los síntomas de 9 medicamentos preidentificados (Antimoniumcrudum, Calcareacarbonicum, Causticum, Dulcamara, Natrummuriaticum, Nitricacidicum, Ruta graveolans, Sulphur, Thujaoccidentalis) como parámetros clínicos para las verrugas.
Materiales y métodos:
El estudio se realizará en 8 centros del CCRH, en los que se aleatorizarán los pacientes que precisan cualquiera de los medicamentos predefinidos para verrugas a un grupo con homeopatía o un grupo de control con placeboconforme a un gráfico de aleatorización generado por ordenador. Los medicamentos seleccionados se prescribirían primero en la potencia de 6c y después a una dosificación y posterior potencia según necesidades. El resultado se basa en el porcentaje de verrugas completamente eliminadas evaluado cada dos semanas durante 6 meses. percentage of warts completely disappeared assessed fortnightly for 6 months.
Discusión: El objetivo del estudio es combinar un ensayo aleatorizado controlado con la validación de síntomas de medicamentos preidentificados para el tratamiento de verrugas. Los síntomas del grupo con el medicamento verdadero de cada caso tratado con éxito se deberán comparar con los del grupo de control. El estudio ha de ayudar a aumentar la eficacia del tratamiento e identificar la sintomatología a partir de la cual se pudieron realizar prescripciones que llevaron al éxito del tratamiento. 
